: TP6.3 g dl, Alb4.3 g dl, GOT17 IU l, GPT26 IU l,
|
|
- Adam Price
- 5 years ago
- Views:
Transcription
1 5 Vol. 34, pp. 5 23, 2006 C IFN 0 2 : C 993 S7 C A F2 IFN IFNa2a 9MIU 24W HCV-RNA F HCV-RNA IFN S8 20 mm CT SPIO-MRI 6 TP6.3 g dl, Alb4.3 g dl, GOT7 IU l, GPT26 IU l, g-gtp40 IU l, ICG5R5, HCV-Ab, HCV-RNA, AFP 3.5 ng ml L3 40, PIVKAII37 mau mg CTA CTAP : IFN 0 IFN 0 C C IFN HCC IFN 0 HCC 57
2 6 Table Fig. Ultrasonography showed hypoechoic lesion in S8 of the liver in size 20 mm. In enhanced ultrasonography, there was no vascular spot in early arterial phase and an avascular area was noted in late parenchymal phase. : 63 : : HCV C IFN IFNa-2a Sustained Virological Response: SVR
3 C SVR 7 Fig. 2 Abdominal CT scan showed low density area in S8 of the liver arrow, and no enhancement on arterial and portal phase S8 5 mm 5 : 53 : : : 75 cm 85 kg BMI C mmhg 70 Table : AFP L3 : S8 20 mm Fig. CT S8 Fig. 2 MRI T T2 SPIO Super paramagnetic iron oxide MRI T2 Fig. 3 CT CTA S8 CT CTAP Fig. 4 HCC 6 8 RFA 4 CT Fig. 5 RFA Fig. 6 Fig IFN 59
4 8 A F IFN A0 F Fig AFP 6ng ml L RFA Fig. 3 In SPIO Super paramagnetic iron oxide MRI the lesion showed high intensity on T2 weighted image arrow. C IFN SVR: sustained virological responder 3 BR: biochemical responder 4 5 IFN 2 3 IFN IFN 5 Toyoda Schwartz IFN mm 9 20 IFN IFN 5 8 NASH Fig. 4 CT arteriography CTA showed tumor lesion with amorphous enhancement in S8. In enhanced CT arterial portography CTAP, the tumor lesion showed a filling defect. 60
5 C SVR 9 C Takase C IFN 2 F AST ALT NASH B C HBV HBc HBs HBV-DNA HBV-DNA HBV C HBc HCV HBV 22 HBc HBV-DNA HBV-DNA HBV Fig. 5 After 4 days of RFA treatment, only a low density area is seen in the area of the tumor. Fig. 6 Histology of tumor lesion ; high cellularity and high ratio of N C were observed with scattered fatty droplets. These findings strongly suggested a well di#erentiated adenocarcinoma. HE 0 Fig. 7 Clinical course 6
6 20 Fig. 8 Before IFN treatment, biopsy showed only mild inflammatory cell infiltration in portal area and moderate fibrosis A F2 a After.2 year of IFN treatment, inflammation had disappeared and revealed only mild fibrosis A0 F b HCC HCC CT MRI T2 CTA CTAP HCC C 5 Shiratori IFN 83 F F2 F F3 F0 IFN 0 IFN IFN IFN 0 IFN 0 Sobesky R, Mathurin P, Charlotte F et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. Gastroenterology 999; 6: Lau DTY, Kleiner DE, Ghany MG et al. 0- year follow-up after interferon-alfa therapy for 62
7 C SVR 2 chronic hepatitis C. Hepatology 998; 28: Marcellin P, Boyer N, Gervais A et al. Longterm histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alfa therapy. Ann. Intern. Med 997; 27: Manesis EK, Papaioannou C, Gioustozi A et al. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 2 months : A 4-year follow-up of 2 patients. Hepatology 997; 26: Reichard O, Glaumann H, Fryden A et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 995; 2: Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C patients who have sustained response to interferon therapy. Annals of Internal Medicine 2000; 32: Lindsay KL. Therapy of hepatitis C: overview. Hepatology 997; 26: s ; 62: IFN C 2000; 4: C ; 99: C 999; 96: Stuart K, Tessitore J, Huberman M et al. 5- Fluorouracil and alfa-interferon in hepatocellular carcinoma. Am J Clin. Oncol 996; 9: C 8 C 998; 39: Yamamura T, Matumoto A, Rokuhara A et al. Development of small hepatocellular carcinoma in a patient with chronic hepatitis C after 77 months of a sustained and complete response to interferon therapy. J. Gastoenterol. Heptol 2002; 7: Kasahara A, Hayashi N, Mochizuki K et al. Risk Factors for Hepatocellular Carcinoma and Its Incidence After Interferon Treatment in patients With Chronic Hepatitis C. Hepatology 998; 27: Ikeda K, Saitoh S, Arase Y et al. E#ect of Interferon Therapy on Hepatocellular Carcinogenesis in Patients With Chronic Hepatitits Type C: A Long-Term Observation Study of 643 Patients Using Stastical Bias Correction With Proportional Hazard Analysis. Hepatology 999: 29; Yoshida H, Shiratori Y, Moriyama M et al. Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Survaillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan. Annals of Internal Medicine 999; 3: Okanoue T, Ito Y. Hepatocellular carcinoma in sustained responders of interferon-treated chronic hepatitis C. J. Gastroenterol. Hepatol. 2003; 8: Schwaltz M. A biomathmatical approach to clinical tumor growth. Cancer 96; 4: Toyoda H, Kumada T, Honda T et al. Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 200; 6: Takase S, Takeda N, Sawada M et al. Relationship between alcoholic liver disease and HCV infection. Alcohol Alcohol 993; 28 A:
8 HBs HCV HBV 999; 40: Parterlini P, Driss F, Nalpas B et al. Persistance of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBs Agnegative patients: A study of a low-endemic area. Hepatology 993; 7: Chung H-T, Lai C-L and Lok A. S. F. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology 995; 22:
9 C SVR 23 Abstract A Case of Hepatocellular Carcinoma Ten Years after Successful Interferon Therapy for Chronic Hepatitis C. Minoru Kobayashi, Michihiro Suzuki, Norie Yamada, Masayo Yamaguchi, Hiroki Ikeda, Hideaki Takahashi, Yoshihiko Nagase, Yoshiki Katakura, Koutarou Matunaga, Toshiya Ishii, Nobuyuki Matsumoto, Chiaki Okuse, Satoshi Kitajima, Junki Koike 2 and Fumio Itoh A 63-year-old man was pointed out liver dysfunction on his medical check-up in 986. He was diagnosed as chronic hepatitis C in 990 on the basis of liver biopsy finding, which showed A F2 in November 993. He was treated with interferon, using 9MIU of interferon-alfa2a, 3 times a week for 24 weeks. He got sustained virological response and normalization of transaminase was observed after the treatment. In Februrary 995, liver biopsy was performed again, fibrosis was improved from F2 to F, and the inflammation had disappeared. In May 2004, a 20 mm liver tumor was noted in S8 on abdominal ultrasonography. He was admitted to our hospital in June of 2004 for further examination. Laboratory data showed elevated alpha-fetoprotein 3.5ng ml and lectin-reactive AFP 40. The tumor showed enhancement on CT arteriography, and defect on CT during arterial portography study. In MRI enhanced with super paramagnetic iron oxide, the lesion was detected with high intensity on T2 weighted image. These data led to the diagnosis of hepatocellular carcinoma HCC and a biopsy was performed. Histological findings of the tumor lesion revealed a high cellularity and high ratio of N C with scattered fatty droplets. These findings strongly suggested a suspected well di#erentiated adenocarcinoma. The tumor was treated with RFA. No recurrence has been found since then. Department of Gastroenterology and Hepatology, St. Marianna University School of Medicine 2 Department of Pathology, St. Marianna University School of Medicine 65
Changes in Clinical Characteristics of Non-B, Non-C Hepatocellular Carcinoma
293 Original Article St. Marianna Med J. Vol. 36, pp. 293301, 2008 Changes in Clinical Characteristics of Non-B, Non-C Hepatocellular Carcinoma Toshiya Ishii 1, Michihiro Suzuki 1, Nobuyuki Matsumoto 1,
More informationDetection and Characterization of Hepatocellular Carcinoma by Imaging
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:S136 S140 Detection and Characterization of Hepatocellular Carcinoma by Imaging OSAMU MATSUI Department of Imaging Diagnosis and Interventional Radiology,
More informationWaseem Hamoudi MD*, Sami Al-Smadi MD*, Karim Lutfi MD*, Moath Azizi MD*, Yousef Niomat MD* ABSTRACT
Durability of Sustained Virological Response and Long Term Follow Up To Pegylated Interferon and Ribavirin in Treated Patients with Chronic Hepatitis C Waseem Hamoudi MD*, Sami Al-Smadi MD*, Karim Lutfi
More informationLong-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon
ORIGINAL ARTICLE Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon Authors Sandro da Costa Ferreira, MD 1 Marcos de Vasconcelos Carneiro, MD 1 Fernanda
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationEighty percent of hepatocellular carcinoma cases are caused by infection with hepatitis B virus
Chapter 1 Prevention Introduction Eighty percent of hepatocellular carcinoma cases are caused by infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). Cases of fatty liver and nonalcoholic
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationChanges in Hepatitis C Virus (HCV) Antibody Status in Patients with Chronic Hepatitis C after Eradication of HCV Infection by Interferon Therapy
MAJOR ARTICLE Changes in Hepatitis C Virus (HCV) Antibody Status in Patients with Chronic Hepatitis C after Eradication of HCV Infection by Interferon Therapy Hidenori Toyoda, 1 Takashi Kumada, 1 Seiki
More informationHepatitis B virus core-related antigen is a serum prediction marker for hepatocellular carcinoma
Editorial Hepatitis B virus core-related antigen is a serum prediction marker for hepatocellular carcinoma Kazunori Kawaguchi, Masao Honda, Shuichi Kaneko Department of Gastroenterology, Kanazawa University
More informationLong term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy
154 LIVER Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy B J Veldt, G Saracco, N Boyer, C Cammà, A Bellobuono, U Hopf, I Castillo,
More informationRelative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection
PO Box 2345, Beijing 123, China World J Gastroenterol 25;11(43):6848-6852 www.wjgnet.com World Journal of Gastroenterology ISSN 17-9327 wjg@wjgnet.com E L S E V I E R 25 The WJG Press and Elsevier Inc.
More informationHepatitis C virus (HCV) is estimated to infect more than REVIEW
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:923 930 REVIEW Effects of a Sustained Virologic Response on Outcomes of Patients With Chronic Hepatitis C VIVIAN NG* and SAMMY SAAB*, *Department of Medicine,
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationThe Diagnosis of Hypovascular Hepatic Lesions Showing Hypo-intensity in the Hepatobiliary Phase of Gd-EOB- DTPA-enhanced MR Imaging in High-risk
2013 67 4 239 244 The Diagnosis of Hypovascular Hepatic Lesions Showing Hypo-intensity in the Hepatobiliary Phase of Gd-EOB- DTPA-enhanced MR Imaging in High-risk Patients for Hepatocellular Carcinoma
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationVol. 35, pp , hepatitis C virus HCV RNA 8 14 HCV RNA. C Genotype 1. Genotype 1b. 1 2 Genotype 2 : 54 :
0 Vol. 35, pp. 007, 2007 C 4 2 3 : 9 4 23 54 2000 7 Genotypeb C C 2005 8 5 3 hepatitis C virus HCV RNA 8 4 HCV RNA C C Genotype 50 2 Genotype 2 36 2 3 4 Genotype b C : 54 : 2000 7 C C 45 02 Table. Laboratory
More informationAtypically large well-differentiated hepatocellular carcinoma with extensive fatty metamorphosis : ReportofaCase
267 CASE REPORT Atypically large well-differentiated hepatocellular carcinoma with extensive fatty metamorphosis : ReportofaCase Daichi Ishikawa, Mitsuo Shimada, Tohru Utsunomiya, Yuji Morine, Satoru Imura,
More informationPrognostic Significance of Simultaneous Measurement of Three Tumor Markers in Patients With Hepatocellular Carcinoma
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:111 117 Prognostic Significance of Simultaneous Measurement of Three Tumor Markers in Patients With Hepatocellular Carcinoma HIDENORI TOYODA,* TAKASHI KUMADA,*
More informationCase Rep Gastroenterol 2010;4: DOI: /
261 Very-Low-Dose Pegylated Interferon α2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention Shogo Ohkoshi Satoshi Yamagiwa Masahiko
More informationSteatosi epatica ed HCV
Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:
More informationTreatment of Chronic Delta Hepatitis: A Nine-Year Retrospective Analysis
. DOI: 10.5812/kowsar.1735143X.728 KOWSAR Journal home page: www.hepatmon.com Treatment of Chronic Delta Hepatitis: A Nine-Year Retrospective Analysis Serda Gulsun 1 *, Recep Tekin 2, Fatma Bozkurt 2 1
More informationHCC and mass effect. Hepatocellular cancer: what if the AFP is rising but no lesion seen on imaging? What you need to know about AFP.
Hepatocellular cancer: what if the AFP is rising but no lesion seen on imaging? Arun J Sanyal M.B.B.S., M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University Imaging features used
More informationApplied Health Economics and Health Policy
Applied Health Economics and Health Policy Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal Elamin H. Elbasha, Jagpreet Chhatwal,
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationDevelopment of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:889 893 Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen MYRON JOHN TONG,*, MICHAEL ONG NGUYEN, LORI TERESE TONG,
More informationReceived 15 April 2012; returned 10 May 2012; revised 14 June 2012; accepted 15 June 2012
J Antimicrob Chemother 212; 67: 2766 2772 doi:1.193/jac/dks269 Advance Access publication 16 August 212 A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationPrimary liver cancer is the third most common. Effect of Aging on Risk for Hepatocellular Carcinoma in Chronic Hepatitis C Virus Infection
Effect of Aging on Risk for Hepatocellular Carcinoma in Chronic Hepatitis C Virus Infection Yasuhiro Asahina, 1 Kaoru Tsuchiya, 1 Nobuharu Tamaki, 1 Itsuko Hirayama, 1 Tomohiro Tanaka, 1 Mitsuaki Sato,
More informationHEPATOCELLULAR CARCINOMA: AN OVERVIEW
HEPATOCELLULAR CARCINOMA: AN OVERVIEW John K. Olynyk Head, Department of Gastroenterology & Hepatology Fiona Stanley Fremantle Hospital Group Dean of Research, Edith Cowan University RISING MORTALITY OF
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationCORRELATION BETWEEN BIOCHEMICAL AND HISTOPATHOLOGICAL PARAMETERS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN
Psychiatria Danubina, 2014; Vol. 26, Suppl. 2, pp S364 S369 Medicina Academica Mostariensia, 2014; Vol. 2, No. 1-2, pp 8-13 Medicinska naklada - Zagreb, Croatia Original paper CORRELATION BETWEEN BIOCHEMICAL
More informationHIV. KEY WORDS: HIV, esophageal varices, endoscopic injection sclerotherapy (EIS), endoscopic variceal ligation (EVL)
2013; 19: 25 32 HIV 1, 2 1 1 1 1 HIV 7 3 HCV, 2 HBV B C 2 HCC 2 F 2 RC 1 2.1 F 1 RC 0 30.4 4 HCV 9 HCC 13.5 3 HCC 1 1 AIDS B C HIV HIV HCV HIV KEY WORDS: HIV, esophageal varices, endoscopic injection sclerotherapy
More informationImproving Treatment Success Rates for HCV in a Managed Care Setting
Improving Treatment Success Rates for HCV in a Managed Care Setting Bruce R. Bacon, MD James F. King MD Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and
More informationSEE EDITORIAL ON PAGE 436 PATIENTS AND METHODS
Interferon Beta Prevents Recurrence of Hepatocellular Carcinoma After Complete Resection or Ablation of the Primary Tumor A Prospective Randomized Study of Hepatitis C Virus Related Liver Cancer KENJI
More informationCriteria Grid Hepatitis C Research Studies, Tools, and Surveillance Systems. Part A. Basic Science Clinical Science Public Health/Epidemiology
Criteria Grid Hepatitis C Research Studies, Tools, and Surveillance Systems Best Practice/Intervention: Date of Review: March 22, 2015 Reviewer(s): Christine Hu Category: Ng V. et al. (2011) Effects of
More informationTitle: Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment
Title: Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment Authors: Yolanda Sánchez-Torrijos, Jara Eloísa Ternero Vega, Carmen Cepeda Franco
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationTreatment of HCC in real life-chinese perspective
Treatment of HCC in real life-chinese perspective George Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond), FAASLD (US) Chairman Humanity and Health Medical Group, Hong Kong SAR, CHINA
More informationONCOLOGY REPORTS 30: 91-98, 2013
ONCOLOGY REPORTS 30: 91-98, 2013 Lack of correlation between the antibody to hepatitis B core antigen and survival after surgical resection for hepatitis C virus-related hepatocellular carcinoma HIROKI
More informationEarly detection and characterization of hepatocellular. Early Detection and Curative Treatment of Early-Stage Hepatocellular Carcinoma
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:S144 S148 Early Detection and Curative Treatment of Early-Stage MASATOSHI KUDO Department of Gastroenterology and Hepatology, Kinki University School of
More informationDetection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection
Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1, Nikolaos K. Gatselis 1, Kalliopi Azariadi
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationAASLD Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital
AASLD 2017 - Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital THE CHANGING LANDSCAPE IN THE TREATMENT OF HCC DISCLAIMER Please note:
More informationAccepted Manuscript. S (16)30397-X Reference: JHEPAT To appear in: Journal of Hepatology
Accepted Manuscript High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis Helder Cardoso, Ana Maria Vale, Susana Rodrigues,
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement
Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Fabien Zoulim Service d hépatologie, Hospices Civils de Lyon INSERM U1052, Cancer
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationThe long-term effects of splenectomy and subsequent interferon therapy in patients with HCV-related liver cirrhosis
MOLECULAR MEDICINE REPORTS 9: 487-492, 2013 The long-term effects of splenectomy and subsequent interferon therapy in patients with HCV-related liver cirrhosis YUJI INAGAKI 1, KAZUSHI SUGIMOTO 1, KATSUYA
More informationViral Hepatitis And Liver Transplantation
Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120
More informationThe Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study
The Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study DK Li, YJ Ren, DS Fierer, S Rutledge, OS Shaikh, V Lo
More informationHealthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The
More informationTumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationHCV HIV +*+ Human immunodeficiency virus HIV hepatitis C virus HCV HIV HCV HCV HIV HIV
,**- The Japanese Society for AIDS Research The Journal of AIDS Research +0 HIV HCV + + + + + + + + +, +, :HCV HIV HAART / : +*+ +*0,**- Human immunodeficiency virus HIV hepatitis C virus HCV HIV,* HCV
More informationHBV (AASLD) CHB, HBV, CHB , ( < 5% ) 11 ( immune tolerant phase) : 21 ( immune clearance phase ) : 31 ( inactive phase) : HBeAg - HBe HBV DNA ALT
2010262 125 R51216 + 2 C 1001-5256 (2010) 02-0125 - 06 2005 12 [ 1 ], (HBV ) (APASL) ( EASL ) (AASLD) (CHB) [ 2 4 ], ( ) ( ), CHB,, CHB CHB,, CHB,, 2 1 HBV hepatitis B virus CHB chronic hepatitis B HB
More informationFATTY LIVER DISEASE (NAFLD) (NASH) A GROWING
NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams
More informationLearning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationANTIVIRAL THERAPY FOR HCV. Alfredo Alberti
CLINICAL IMPACT OF SVR AFTER ANTIVIRAL THERAPY FOR HCV Alfredo Alberti Department of Histology,Microbiology and Medical Biotechnologies Molecular Hepatology Unit Venetian Institute of Molecular Medicine
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationThe Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
Gut and Liver, Published online August 14, 2017 ORiginal Article The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients Shinya Taki 1, Hideyuki Tamai 1, Yoshiyuki Ida 1,
More informationNIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:
ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis
More informationAbstract and Introduction. Patients and Methods. M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S.
www.medscape.com Cirrhosis, High Age and High Body Mass Index Are Risk Factors for Persisting Advanced Fibrosis After Sustained Virological Response in Chronic Hepatitis C M. Hedenstierna; A. Nangarhari;
More informationRisk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화
Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk factors for HCC development (I) Environmental factors Infectious HBV HCV HDV Alimentary Alcohol Diet High
More informationThe Long Term Care Risk
Hepatitis C The Long Term Care Risk Objectives Basics of the disease Disease progression Comorbid factors Treatment Long term care risk Basics of Hepatitis C Caused by an RNA virus Clinical Course Acute
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationUltrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview.
Review Med Ultrason 2014, Vol. 16, no. 2, 139-144 DOI: Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview. Mirela Dănilă, Ioan Sporea Gastroenterology
More informationHepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
More informationGI DISEASE WORKSHOP CASE STUDIES
GI DISEASE WORKSHOP CASE STUDIES American Academy of Insurance Medicine Triennial Course in Insurance Medicine 2012 Clifton Titcomb Jr., MD (Hannover Re) James Topic, MD (Protective Life) 1 CASE #1 Application
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationHepatitis C wi w t i h Ju J dy y W y W a y t a t t
Hepatitis C with Judy Wyatt Hepatitis C and the histopathologist Pre-2006 biopsy based treatment of moderate-severe chronic hepatitis Now biopsy for: Watchful waiting, to confirm mild disease? Cirrhosis
More informationHepatitis C Update on New Treatments
Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts
More informationMore than 2 billion people worldwide have
Long-Term Entecavir Treatment Reduces Hepatocellular Carcinoma Incidence in Patients With Hepatitis B Virus Infection Tetsuya Hosaka, 1 Fumitaka Suzuki, 1 Masahiro Kobayashi, 1 Yuya Seko, 1 Yusuke Kawamura,
More informationHBV Core and Core-Related Antigen Quantitation in Chinese Patients with. Chronic Hepatitis B Genotype B and C Virus Infection
Title page HBV Core and Core-Related Antigen Quantitation in Chinese Patients with Chronic Hepatitis B Genotype B and C Virus Infection Short Title: Quantitation of HBc and HBcrAg in Chinese patients Akinori
More information/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT
原 著 29 34-41, 2014 FIB4 Index 1 1 1 1 2 1 1 FIB4 Index FIB4 Index cut off 2.67 2.67 12,059 FIB4 IndexFIB4 Index 2.67 / FIB4 Index AST ALT FIB4 Index 2.67 161 1.3% FIB4 Index 5 FIB4 Index 1.1 5 1.6 FIB4
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More information